TRINITY BIOTECH PLC-SPON ADR (TRIB) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:TRIB • US8964385046

0.7783 USD
0 (-0.45%)
At close: Feb 4, 2026
0.7551 USD
-0.02 (-2.98%)
After Hours: 2/4/2026, 8:00:01 PM
Fundamental Rating

2

Taking everything into account, TRIB scores 2 out of 10 in our fundamental rating. TRIB was compared to 186 industry peers in the Health Care Equipment & Supplies industry. TRIB may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, TRIB is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year TRIB has reported negative net income.
  • In the past year TRIB has reported a negative cash flow from operations.
  • In the past 5 years TRIB reported 4 times negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: TRIB reported negative operating cash flow in multiple years.
TRIB Yearly Net Income VS EBIT VS OCF VS FCFTRIB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M -100M

1.2 Ratios

  • TRIB has a Return On Assets (-30.78%) which is in line with its industry peers.
Industry RankSector Rank
ROA -30.78%
ROE N/A
ROIC N/A
ROA(3y)-38.57%
ROA(5y)-23.97%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TRIB Yearly ROA, ROE, ROICTRIB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K 1.5K

1.3 Margins

  • TRIB has a worse Gross Margin (34.83%) than 73.66% of its industry peers.
  • TRIB's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for TRIB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 34.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.46%
GM growth 5Y-3.74%
TRIB Yearly Profit, Operating, Gross MarginsTRIB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • TRIB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, TRIB has about the same amount of shares outstanding.
  • The number of shares outstanding for TRIB has been increased compared to 5 years ago.
  • TRIB has a better debt/assets ratio than last year.
TRIB Yearly Shares OutstandingTRIB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
TRIB Yearly Total Debt VS Total AssetsTRIB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -0.88, we must say that TRIB is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of TRIB (-0.88) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.88
ROIC/WACCN/A
WACC7.2%
TRIB Yearly LT Debt VS Equity VS FCFTRIB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • TRIB has a Current Ratio of 1.28. This is a normal value and indicates that TRIB is financially healthy and should not expect problems in meeting its short term obligations.
  • TRIB has a Current ratio of 1.28. This is in the lower half of the industry: TRIB underperforms 79.57% of its industry peers.
  • TRIB has a Quick Ratio of 1.28. This is a bad value and indicates that TRIB is not financially healthy enough and could expect problems in meeting its short term obligations.
  • TRIB has a worse Quick ratio (0.68) than 87.10% of its industry peers.
Industry RankSector Rank
Current Ratio 1.28
Quick Ratio 0.68
TRIB Yearly Current Assets VS Current LiabilitesTRIB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • TRIB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.67%, which is quite good.
  • Looking at the last year, TRIB shows a quite strong growth in Revenue. The Revenue has grown by 8.31% in the last year.
  • Measured over the past years, TRIB shows a decrease in Revenue. The Revenue has been decreasing by -7.41% on average per year.
EPS 1Y (TTM)16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16%
Revenue 1Y (TTM)8.31%
Revenue growth 3Y-8.8%
Revenue growth 5Y-7.41%
Sales Q2Q%18.09%

3.2 Future

  • Based on estimates for the next years, TRIB will show a very strong growth in Earnings Per Share. The EPS will grow by 34.68% on average per year.
  • TRIB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.62% yearly.
EPS Next Y65.8%
EPS Next 2Y34.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year10.13%
Revenue Next 2Y11.62%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TRIB Yearly Revenue VS EstimatesTRIB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
TRIB Yearly EPS VS EstimatesTRIB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -5 -10

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TRIB. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TRIB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRIB Price Earnings VS Forward Price EarningsTRIB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRIB Per share dataTRIB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

  • TRIB's earnings are expected to grow with 34.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.68%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • TRIB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TRINITY BIOTECH PLC-SPON ADR

NASDAQ:TRIB (2/4/2026, 8:00:01 PM)

After market: 0.7551 -0.02 (-2.98%)

0.7783

0 (-0.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-13
Earnings (Next)04-03
Inst Owners24.88%
Inst Owner Change2.04%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap14.94M
Revenue(TTM)61.56M
Net Income(TTM)-31.79M
Analysts85.71
Price TargetN/A
Short Float %N/A
Short Ratio0.09
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-128.03%
Min EPS beat(2)-272.55%
Max EPS beat(2)16.49%
EPS beat(4)1
Avg EPS beat(4)-116.51%
Min EPS beat(4)-272.55%
Max EPS beat(4)16.49%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-7.88%
Min Revenue beat(2)-9.97%
Max Revenue beat(2)-5.78%
Revenue beat(4)0
Avg Revenue beat(4)-6.76%
Min Revenue beat(4)-9.97%
Max Revenue beat(4)-1.38%
Revenue beat(8)1
Avg Revenue beat(8)-7.57%
Revenue beat(12)1
Avg Revenue beat(12)-11.44%
Revenue beat(16)3
Avg Revenue beat(16)-13.23%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.24
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.68
EYN/A
EPS(NY)-0.92
Fwd EYN/A
FCF(TTM)-0.74
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS3.21
BVpS-1.83
TBVpS-4.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -30.78%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 34.83%
FCFM N/A
ROA(3y)-38.57%
ROA(5y)-23.97%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.46%
GM growth 5Y-3.74%
F-Score4
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 539.63%
Cap/Sales 16.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.28
Quick Ratio 0.68
Altman-Z -0.88
F-Score4
WACC7.2%
ROIC/WACCN/A
Cap/Depr(3y)316%
Cap/Depr(5y)319.23%
Cap/Sales(3y)10.22%
Cap/Sales(5y)10.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16%
EPS Next Y65.8%
EPS Next 2Y34.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)8.31%
Revenue growth 3Y-8.8%
Revenue growth 5Y-7.41%
Sales Q2Q%18.09%
Revenue Next Year10.13%
Revenue Next 2Y11.62%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-12.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.74%
OCF growth 3YN/A
OCF growth 5YN/A

TRINITY BIOTECH PLC-SPON ADR / TRIB FAQ

What is the fundamental rating for TRIB stock?

ChartMill assigns a fundamental rating of 2 / 10 to TRIB.


Can you provide the valuation status for TRINITY BIOTECH PLC-SPON ADR?

ChartMill assigns a valuation rating of 1 / 10 to TRINITY BIOTECH PLC-SPON ADR (TRIB). This can be considered as Overvalued.


Can you provide the profitability details for TRINITY BIOTECH PLC-SPON ADR?

TRINITY BIOTECH PLC-SPON ADR (TRIB) has a profitability rating of 1 / 10.


Is the dividend of TRINITY BIOTECH PLC-SPON ADR sustainable?

The dividend rating of TRINITY BIOTECH PLC-SPON ADR (TRIB) is 0 / 10 and the dividend payout ratio is 0%.